• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    South America Geographic Atrophy (GA) Market

    ID: MRFR/HC/49913-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    South America Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography), By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) and By Regional (Brazil, Mexico, Argentina, Rest of South America)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    South America Geographic Atrophy (GA) Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    South America Geographic Atrophy (GA) Market Summary

    The South America Geographic Atrophy market is projected to grow from 1.08 USD Billion in 2024 to 2.24 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    South America Geographic Atrophy GA Key Trends and Highlights

    • The market is expected to reach 2.24 USD Billion by the year 2035, indicating a substantial increase from the base year valuation of 1.08 USD Billion in 2024.
    • The compound annual growth rate (CAGR) for the South America Geographic Atrophy market is estimated at 6.86% from 2025 to 2035.
    • This growth trajectory suggests a rising demand for innovative treatment options in the region.
    • Growing adoption of advanced diagnostic technologies due to increasing prevalence of age-related macular degeneration is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.08 (USD Billion)
    2035 Market Size 2.24 (USD Billion)
    CAGR (2025-2035) 6.86%

    Major Players

    Carl Zeiss AG, Eyegate Pharmaceuticals, Envisia Therapeutics, Novartis, Hugel, Kowa Company, Bayer, Fitzgerald Industries International, Astellas Pharma, Alder Biopharmaceuticals, Roche, Eyenovia, Regeneron Pharmaceuticals, Alcon

    South America Geographic Atrophy (GA) Market Trends

    In South America, the Geographic Atrophy (GA) market is experiencing significant developments driven by an aging population and increasing awareness of age-related macular degeneration. With life expectancy rising in countries like Brazil and Argentina, the prevalence of GA is also growing, urging healthcare providers to prioritize research and treatment options. The demand for innovative therapies is further catalyzed by advancements in technology and increased focus on ophthalmology research, aiming to provide better diagnostic tools and treatment solutions. times have observed a surge in collaborations among pharmaceutical firms and research institutions in South America.

    This trend is notable in countries like Chile and Colombia, where clinical trials are gaining pace, allowing for a quicker understanding of GA treatment efficacy. Telemedicine and digital health solutions are finding a foothold in the South American healthcare landscape, offering remote access to specialists and facilitating early diagnosis and intervention for at-risk patients. Despite challenges, there are opportunities to be explored in the South American GA market. The incorporation of artificial intelligence in diagnosing eye diseases represents a promising frontier, enhancing precision and patient outcomes.

    Moreover, new policies aimed at improving healthcare access, particularly in rural areas, could facilitate better treatment for GA patients.Overall, with the combination of rising public health initiatives and technological innovations, the South American Geographic Atrophy market shows substantial potential for growth and improvement in patient care.

    Market Segment Insights

    Geographic Atrophy GA Market Age Group Insights

    The Age Group segmentation within the South America Geographic Atrophy GA Market reveals critical insights into the demographic trends shaping this sector. The population aged above 60 years is steadily increasing in South America, primarily due to longer life expectancies and improved healthcare systems, particularly in countries such as Brazil, Argentina, and Chile. This age group is extremely significant, as they tend to exhibit higher rates of geographic atrophy, making them a primary focus for the industry.

    As the population continues to age, there is an escalating demand for medical treatments aimed at mitigating the effects of age-related vision loss, highlighting the need for innovative therapies and supportive measures.

    In the Age Group of Above 75 years, the significance further amplifies due to the heightened prevalence of age-related conditions, including macular degeneration, which directly impacts vision quality. This demographic represents a vital part of the South America Geographic Atrophy GA Market as they typically require more intensive medical management and care options. Healthcare policies in South America are increasingly addressing the requirements for this elderly population, thus presenting valuable opportunities for stakeholders in the market aiming to cater to their needs.

    The growing awareness of geographic atrophy and its implications among healthcare providers and patients alike is also contributing to the market's expansion. Moreover, advancements in research and development are yielding promising outcomes, fostering a collaborative effort between various entities to improve treatment strategies and enhance patient outcomes.

    Overall, the Age Group segmentation indicates a clear focus on older adults as a critical market segment, emphasizing a collective responsibility towards developing effective healthcare solutions for the elderly population facing geographic atrophy and related issues in South America.

    Geographic Atrophy GA Market Diagnosis Insights

    The Diagnosis segment of the South America Geographic Atrophy GA Market plays a crucial role in the effective identification and assessment of geographic atrophy, a leading cause of vision loss. With a market poised for significant growth, the focus on advanced diagnostic technologies is becoming essential. Fundus Autofluorescence is critical as it provides detailed imaging of retinal tissues, enabling early detection of changes, which is vital for timely intervention. Similarly, Optical Coherence Tomography Angiography offers non-invasive imaging that enhances the visualization of retinal vascular structure, thus offering invaluable insights for clinical decision-making.

    Multifocal Electroretinography complements these techniques by assessing retinal function across various regions, providing a comprehensive evaluation that supports more tailored treatment strategies. As the South American population ages, increased prevalence of age-related macular degeneration necessitates the widespread adoption of these advanced diagnostic tools. The combination of these techniques represents a holistic approach to managing geographic atrophy, presenting opportunities for healthcare providers to enhance patient outcomes in this region.The South America Geographic Atrophy GA Market is characterized by a growing demand for innovative diagnostic solutions that are essential for combating this debilitating condition effectively.

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights

    The Therapeutic Agents Clinical Phase segment within the South America Geographic Atrophy GA Market is critical to enhancing treatment options and improving patient outcomes. This segment comprises various stages of drug development, including Late-Stage, Phase II, Phase I, Pre-Clinical Stage, and Discovery Candidates. Late-Stage therapies typically draw significant attention as they are closest to entering the market, holding promise for effective interventions. Meanwhile, Phase II trials focus on expanding understanding of treatment efficacy and safety, becoming essential for subsequent regulatory approvals.

    Phase I trials initiate safety testing in a small group of individuals, laying the foundation for further development. The Pre-Clinical Stage is vital in identifying potential therapeutic candidates before human trials, while Discovery Candidates represent innovative approaches to treatment that could reshape management of Geographic Atrophy.

    The South America region, with its aging population and rising prevalence of eye-related diseases, presents substantial opportunities for growth in these clinical phases, fueled by a combination of academic research, emerging biotech companies, and increasing investment in Research and Development.These dynamics collectively reflect the critical importance of the Therapeutic Agents Clinical Phase segment, positioning it as a key driver of progress in the management of Geographic Atrophy in South America.

    Get more detailed insights about South America Geographic Atrophy (GA) Market Research Report - Forecast To 2035

    Regional Insights

    The South America Geographic Atrophy GA Market is characterized by diverse regional dynamics that significantly contribute to market growth and segmentation. Brazil stands out as a significant player in this market due to its large population and high incidence of age-related macular degeneration, which drives demand for treatment options. Mexico also plays a crucial role with its expanding healthcare infrastructure and rising awareness about vision health, making it a growing market for Geographic Atrophy solutions.

    Argentina, with its increasing healthcare investment, is seeing enhanced access to advanced treatment methods, thus contributing to the overall market expansion.The Rest of South America is noteworthy, as it encompasses various countries that are gradually increasing health expenditures and adopting innovative therapies. 

    The combination of an aging population, increasing prevalence of chronic eye diseases, and advancements in medical technology are key growth driver across these regions. Furthermore, opportunities arise from the growing collaboration among healthcare providers and pharmaceutical companies to enhance treatment accessibility and affordability in the South America Geographic Atrophy GA Market.Understanding these regional characteristics is essential for stakeholders looking to optimize their strategies and meet the unique needs of the South American population.

    South America Geographic Atrophy (GA) Market Region

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The South America Geographic Atrophy GA Market is characterized by a burgeoning landscape driven by an increase in the aging population and a heightened prevalence of retinal diseases, particularly age-related macular degeneration. This market is witnessing intensified competition as various players strive to establish a foothold through innovative treatment options, advanced technologies, and strategic collaborations. The competitive dynamics are shaped by several factors including regulatory harmonization, shifting healthcare policies, and growing awareness among patients and healthcare providers about the significance of early diagnosis and intervention in managing Geographic Atrophy. 

    Companies are innovating their product pipelines to address unmet medical needs while also focusing on improving patient outcomes, thereby making this region a significant area for investment and growth in the ophthalmological sector.Carl Zeiss AG has significantly established its presence in the South American Geographic Atrophy GA Market through its advanced imaging solutions and diagnostic tools tailored for ophthalmology. The company's strengths lie in its robust R&D capabilities, allowing continuous innovation in visualization and precision measurement technologies that aid in the early detection of retinal conditions, including Geographic Atrophy.

    Its extensive distribution network in South America fosters a strong market presence, and partnerships with healthcare institutions enhance its credibility and reach. 

    The company's commitment to training and education for local healthcare practitioners further strengthens its position in the market, enabling better patient management for those suffering from sight-threatening conditions.Eyegate Pharmaceuticals is also a key player in the South American Geographic Atrophy GA Market, particularly known for its novel drug delivery systems and innovative therapies aimed at treating retinal diseases. The company focuses on developing biopharmaceutical products that allow for less invasive treatment options, thereby addressing a critical gap in the current treatment landscape. 

    Eyegate's strengths lie in its proprietary technologies that promise to enhance drug absorption and efficacy in the ophthalmic domain. The company has been pursuing strategic partnerships and collaborations within South America to expand its market reach and drive the commercial success of its key products. Eyegate's commitment to innovation is underscored by its active engagement in clinical trials and research initiatives designed to bolster its therapeutic offerings, ultimately enhancing patient outcomes in the region.

    Key Companies in the South America Geographic Atrophy (GA) Market market include

    Industry Developments

    In the South America Geographic Atrophy (GA) Market, recent developments indicate a notable increase in Research and Development investments focusing on therapeutic options and diagnostic tools targeted at retinal diseases. Companies such as Novartis and Bayer are making strides with innovative treatment approaches, while Alcon has expanded its product offering in the region to cater to the growing demand for ophthalmic solutions. In September 2023, EyeGate Pharmaceuticals announced an agreement with a South American distributor to enhance the availability of its GA treatments.

    Additionally, Kowa Company reported improved market penetration through partnerships with local health authorities in Brazil. Notably, in August 2023, Roche expanded its collaboration with Astellas Pharma, aiming to accelerate the development of new therapies for macular degeneration, thus strengthening their presence in the South American market. The valuation of the Geographic Atrophy market is expected to rise due to increasing patient awareness and government initiatives to support eye health, particularly in Argentina and Chile.

    Over the past couple of years, significant efforts to increase accessibility to treatments have been observed, contributing positively to the evolving landscape of the Geographic Atrophy market in South America.

    Market Segmentation

    Outlook

    • Brazil
    • Mexico
    • Argentina
    • Rest of South America

    Geographic Atrophy GA Market Regional Outlook

    • Brazil
    • Mexico
    • Argentina
    • Rest of South America

    Geographic Atrophy GA Market Age Group Outlook

    • Above 60 Years
    • Above 75 Years

    Geographic Atrophy GA Market Diagnosis Outlook

    • Fundus Autofluorescence
    • Optical Coherence Tomography Angiography
    • Multifocal Electroretinography

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.08(USD Billion)
    MARKET SIZE 2024 1.11(USD Billion)
    MARKET SIZE 2035 2.24(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.579% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Carl Zeiss AG, Eyegate Pharmaceuticals, Envisia Therapeutics, Novartis, Hugel, Kowa Company, Bayer, Fitzgerald Industries International, Astellas Pharma, Alder Biopharmaceuticals, Roche, Eyenovia, Regeneron Pharmaceuticals, Alcon
    SEGMENTS COVERED Age Group, Diagnosis, Therapeutic Agents Clinical Phase, Regional
    KEY MARKET OPPORTUNITIES Rising elderly population, Increasing awareness programs, Growing prevalence of diabetes, Expanding telemedicine services, Development of novel therapies
    KEY MARKET DYNAMICS Increasing elderly population, Rising prevalence of GA, Limited treatment options, Growing awareness initiatives, Advancements in diagnostic technology
    COUNTRIES COVERED Brazil, Mexico, Argentina, Rest of South America

    FAQs

    What is the expected market size of the South America Geographic Atrophy GA Market in 2024?

    The South America Geographic Atrophy GA Market is expected to be valued at 1.11 USD Billion in 2024.

    What is the projected market size for the South America Geographic Atrophy GA Market by 2035?

    By 2035, the South America Geographic Atrophy GA Market is anticipated to reach a valuation of 2.24 USD Billion.

    What is the expected CAGR for the South America Geographic Atrophy GA Market from 2025 to 2035?

    The expected CAGR for the South America Geographic Atrophy GA Market during the forecast period from 2025 to 2035 is 6.579%.

    Which country holds the largest market share in the South America Geographic Atrophy GA Market?

    Brazil holds the largest market share in the South America Geographic Atrophy GA Market with a valuation of 0.45 USD Billion in 2024.

    What is the projected market size for Argentina in the South America Geographic Atrophy GA Market by 2035?

    By 2035, the market size for Argentina in the South America Geographic Atrophy GA Market is projected to reach 0.4 USD Billion.

    Who are the key players in the South America Geographic Atrophy GA Market?

    Key players in the market include major companies such as Novartis, Bayer, and Regeneron Pharmaceuticals.

    What is the expected market size for the segment of individuals above 75 years in 2024?

    The market size for individuals above 75 years is expected to be 0.38 USD Billion in 2024.

    How does the Rest of South America region contribute to the Geographic Atrophy GA Market?

    The Rest of South America region is valued at 0.21 USD Billion in 2024, contributing significantly to the overall market.

    What market growth rate is expected for Brazil specifically between 2025 and 2035?

    Brazil is expected to experience notable market growth with an increase from 0.45 USD Billion in 2024 to 0.91 USD Billion in 2035.

    What are some key growth drivers for the South America Geographic Atrophy GA Market?

    Key growth drivers include an aging population and advancements in treatment options for geographic atrophy.

    South America Geographic Atrophy (GA) Market Research Report - Forecast To 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials